Gaston Geenslaan 1
3001 Leuven


reMYND NV, founded in 2002 as a spin-off from the University of Leuven, drives the development of disease-modifying treatments against Alzheimer’s, Parkinson’s, Diabetes and other orphan protein misfolding disorders.

reMYND is organized along two independently managed business units, the Contract Research Organization (CRO) and the own Drug Discovery & Development unit:

Contract Research

The in-vivo Contract Research Organization (CRO) helps its clients assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease in reMYND’s proprietary Alzheimer mouse models. Its mission is to be a strategic partner for its clients and help them identify the most promising set-up to assess potential effects. Given the extensive experience fully focused on Alzheimer's, reMYND’s CRO can contribute its expertise for every type of Alzheimer treatment in any form of application. The CRO is serving 6 of the Top 10 pharmaco’s worldwide and its client-base covers the US, Europe and Japan. The CRO has provided in-vivo proof-of-concept data for several candidate drugs that reMYND’s clients have currently in clinical development

Drug discovery

reMYND’s own Drug Discovery & Development unit focuses entirely on disease-modifying treatments with the aim to decelerate – or even reverse – cellular degeneration found in protein misfolding disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), type 2 diabetes mellitus (T2DM) and several orphan diseases. As such, reMYND responds to a clear unmet medical need, as all marketed treatments and the majority of the products under development world-wide are aimed mainly to mitigate symptoms.

reMYND’s pipeline primarily consists of 4 disease-modifying programs counteracting tau-toxicity for AD, 2 programs for T2DM, and 2 counteracting synuclein-toxicity for PD, with recent additions in orphan diseases.